Get the Stockscreener App
2.34
1.27%
-0.03
After Hours:
2.38
0.04
+1.71%
Dare Bioscience Inc stock is traded at $2.34, with a volume of 232.84K.
It is down -1.27% in the last 24 hours and up +10.90% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$2.37
Open:
$2.34
24h Volume:
232.84K
Relative Volume:
0.41
Market Cap:
$35.05M
Revenue:
$1.03M
Net Income/Loss:
$-13.40M
P/E Ratio:
-1.7575
EPS:
-1.3314
Net Cash Flow:
$-10.27M
1W Performance:
+4.00%
1M Performance:
+10.90%
6M Performance:
+29.28%
1Y Performance:
-19.31%
1-Day Range:
$2.30
$2.40
1-Week Range:
$2.2501
$2.50
52-Week Range:
$1.27
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.34 | 35.50M | 1.03M | -13.40M | -10.27M | -1.3314 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dare Bioscience Inc Stock (DARE) Latest News
Dare Bioscience (DARE) Secures Final $1M Grant from NIH for HPV Treatment - GuruFocus
Daré Bioscience receives second $1M NIH funding tranche By Investing.com - Investing.com South Africa
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - The Manila Times
NIH backs $2M HPV treatment push targeting cervical cancer cause - Stock Titan
Dare Bioscience Inc (DARE) Stock Price, Quote, News & History - Benzinga
Earnings call transcript: Dare Bioscience outlines liquidity and revenue plans in Q1 2026 By Investing.com - Investing.com South Africa
Earnings call transcript: Dare Bioscience outlines liquidity and revenue plans in Q1 2026 - Investing.com
Dare Bioscience, Inc.Common Stock (NQ: DARE - The Chronicle-Journal
Maxim Group Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies - Sahm
Dare Bioscience (DARE) Launches Phase 2 Study for DARE-HPV Treat - GuruFocus
Daré Bioscience Completes Regulation A Investor Unit Offering - TipRanks
Dare Bioscience completes closing of Regulation A equity offering By Investing.com - Investing.com South Africa
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience (NASDAQ: DARE) issues 50,000 preferred unit package - Stock Titan
Dare Bioscience Q3 2025 Earnings Preview - MSN
Daré Bioscience begins phase 2 trial for HPV treatment By Investing.com - Investing.com South Africa
Daré Bioscience initiates phase 2 study of Dare-HPV - marketscreener.com
Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv - TradingView
Daré Bioscience begins phase 2 trial for HPV treatment - Investing.com
Daré Bioscience Initiates Phase 2 Study for DARE-HPV, Potential First Pharmacologic Treatment for High-Risk HPV Infection - Quiver Quantitative
6M women get high-risk HPV yearly; new trial tests first potential drug - Stock Titan
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Q1 2026 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update - Sahm
Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Str - GuruFocus
Daré Bioscience Releases Q1 2026 Financial Results - AlphaStreet
Daré Bioscience (DARE) Reports Positive Developments and Financi - GuruFocus
Daré Bioscience targets Ovaprene Phase III to reach 2,500 exposure cycles in 2026 as Flora Sync LF5 revenue is expected to begin in June - MSN
Dare Bioscience (DARE) Q1 2026: EPS -$0.20 vs -$0.27 est (beat); - GuruFocus
Earnings call transcript: Dare Bioscience sees stock uptick, product launch By Investing.com - Investing.com Nigeria
Earnings call transcript: Dare Bioscience sees stock uptick, product launch - Investing.com
Dare Bioscience Q1 2026 Earnings Call: Complete Transcript - Benzinga
Dare Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Dare Bioscience Revenue From DARE to RECLAIM Is Targeted to Begin in 2027 >DARE - Moomoo
Daré Bioscience (NASDAQ:DARE) Q1 2026 Results Show Mixed Bag with Revenue Miss but EPS Beat and Upcoming Product Launches - ChartMill
DARE BIOSCIENCE ($DARE) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Dare Bioscience | 10-Q: Q1 2026 Earnings Report - Moomoo
Daré Bioscience (NASDAQ: DARE) narrows Q1 loss but flags going concern risk - Stock Titan
Daré Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Daré Bioscience (NASDAQ: DARE) details Q1 loss and 2026–27 revenue milestones - Stock Titan
Press Release: Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Dare Bioscience Q1 2026 earnings preview - MSN
12 Health Care Stocks Moving In Thursday's After-Market Session - Sahm
Why is nano-cap Dare Bioscience stock trading higher on Tuesday? - MSN
Dare Bioscience Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday? - Benzinga
Daré Bioscience reports interim phase 3 data for Ovaprene - Investing.com India
Dare Bioscience IncNo Serious Adverse Even - Moomoo
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):